Can Partnering with a CDMO reduce Risk for Pharma Companies?

Medicines development specialist CatSci Ltd has commissioned a new material science laboratory as part of its £3 million investment plan to expand its integrated drug development capabilities. The new lab, expected to be open at the beginning of June 2021, will provide solid state expertise for both emerging and established pharma companies.

Dr Ross Burn, CEO, said: “Expanding our material science capabilities will enable us to provide a fully sustainable, integrated solution that will ultimately de-risk our customers’ pharmaceutical pipeline. Our agile, end-in-mind approach adds true value to both our core customer segments: it helps maximise the chance of small molecule success for emerging pharma companies and by taking a data-rich approach earlier in the process, we can minimise risks in the latter stages of drug development for large pharma companies.”

Dr Robert Dennehy, Director of Crystallisation and Solid State, said: “By linking an API’s physical properties and pre-formulation development, CatSci aims to break down the silos between drug substance and drug product, expediting medicines development. In addition, the crystallisation development step in small molecule drug development can be one of the most environmentally damaging and less well understood. Opening this lab expands our ability to design and develop scalable and robust crystallisations for our customers, improving the economic and environmental sustainability of their pharmaceutical manufacturing processes. 

“Our experience and expertise across the CMC landscape mean that we fully understand our customers’ project challenges and deliver tailored solutions right first time, every time.”
To celebrate the company will be holding a virtual material science symposium on ‘Material Science in Drug Development: A Holistic Approach’ on 3rd June 2021.

Further information online